BACKGROUND: The optimal type of stem cell for use in patients with ischemic heart disease has not been determined. A primitive population of bone marrow-derived hematopoietic cells has been isolated by the presence of the enzyme aldehyde dehydrogenase and comprises a multilineage mix of stem and progenitor cells. Aldehyde dehydrogenase-bright (ALDH(br)) cells have shown promise in promoting angiogenesis and providing perfusion benefits in preclinical ischemia studies. We hypothesize that ALDH(br) cells may be beneficial in treating ischemic heart disease and thus conducted the first randomized, controlled, double-blind study to assess the safety of the transendocardial injection of autologous ALDH(br) cells isolated from the bone marrow in patients with advanced ischemic heart failure. METHODS:Aldehyde dehydrogenase-bright cells were isolated from patients' bone marrow on the basis of the expression of a functional (aldehyde dehydrogenase) marker. We enrolled 20 patients (treatment, n = 10; control, n = 10). Safety (primary end point) and efficacy (secondary end point) were assessed at 6 months. RESULTS: No major adverse cardiovascular or cerebrovascular events occurred in ALDH(br)-treated patients in the periprocedural period (up to 1 month); electromechanical mapping-related ventricular tachycardia (n = 2) and fibrillation (n = 1) occurred in control patients. Aldehyde dehydrogenase-bright-treated patients showed a significant decrease in left ventricular end-systolic volume at 6 months (P = .04) and a trend toward improved maximal oxygen consumption. The single photon emission computed tomography delta analysis showed a trend toward significant improvement in reversibility in cell-treated patients (P = .053). CONCLUSIONS: We provide preliminary evidence that treatment with the novel cell population, ALDH(br) cells, is safe and may provide perfusion and functional benefits in patients with chronic myocardial ischemia. Copyright Â
RCT Entities:
BACKGROUND: The optimal type of stem cell for use in patients with ischemic heart disease has not been determined. A primitive population of bone marrow-derived hematopoietic cells has been isolated by the presence of the enzyme aldehyde dehydrogenase and comprises a multilineage mix of stem and progenitor cells. Aldehyde dehydrogenase-bright (ALDH(br)) cells have shown promise in promoting angiogenesis and providing perfusion benefits in preclinical ischemia studies. We hypothesize that ALDH(br) cells may be beneficial in treating ischemic heart disease and thus conducted the first randomized, controlled, double-blind study to assess the safety of the transendocardial injection of autologous ALDH(br) cells isolated from the bone marrow in patients with advanced ischemic heart failure. METHODS: Aldehyde dehydrogenase-bright cells were isolated from patients' bone marrow on the basis of the expression of a functional (aldehyde dehydrogenase) marker. We enrolled 20 patients (treatment, n = 10; control, n = 10). Safety (primary end point) and efficacy (secondary end point) were assessed at 6 months. RESULTS: No major adverse cardiovascular or cerebrovascular events occurred in ALDH(br)-treated patients in the periprocedural period (up to 1 month); electromechanical mapping-related ventricular tachycardia (n = 2) and fibrillation (n = 1) occurred in control patients. Aldehyde dehydrogenase-bright-treated patients showed a significant decrease in left ventricular end-systolic volume at 6 months (P = .04) and a trend toward improved maximal oxygen consumption. The single photon emission computed tomography delta analysis showed a trend toward significant improvement in reversibility in cell-treated patients (P = .053). CONCLUSIONS: We provide preliminary evidence that treatment with the novel cell population, ALDH(br) cells, is safe and may provide perfusion and functional benefits in patients with chronic myocardial ischemia. Copyright Â
Authors: Emerson C Perin; Michael Murphy; John P Cooke; Lem Moyé; Timothy D Henry; Judy Bettencourt; Amir Gahremanpour; Nicholas Leeper; R David Anderson; William R Hiatt; Joao A Lima; Bharath Venkatesh; Shelly L Sayre; Rachel W Vojvodic; Doris A Taylor; Ray F Ebert; Alan T Hirsch Journal: Am Heart J Date: 2014-07-30 Impact factor: 4.749
Authors: Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn Journal: Circ Res Date: 2015-07-09 Impact factor: 17.367
Authors: Emerson C Perin; Michael P Murphy; Keith L March; Roberto Bolli; John Loughran; Phillip C Yang; Nicholas J Leeper; Ronald L Dalman; Jason Alexander; Timothy D Henry; Jay H Traverse; Carl J Pepine; R David Anderson; Scott Berceli; James T Willerson; Raja Muthupillai; Amir Gahremanpour; Ganesh Raveendran; Omaida Velasquez; Joshua M Hare; Ivonne Hernandez Schulman; Vijaykumar S Kasi; William R Hiatt; Bharath Ambale-Venkatesh; João A Lima; Doris A Taylor; Micheline Resende; Adrian P Gee; April G Durett; Jeanette Bloom; Sara Richman; Patricia G'Sell; Shari Williams; Fouzia Khan; Elsie Gyang Ross; Michelle R Santoso; JoAnne Goldman; Dana Leach; Eileen Handberg; Benjamin Cheong; Nichole Piece; Darcy DiFede; Barb Bruhn-Ding; Emily Caldwell; Judy Bettencourt; Dejian Lai; Linda Piller; Lara Simpson; Michelle Cohen; Shelly L Sayre; Rachel W Vojvodic; Lem Moyé; Ray F Ebert; Robert D Simari; Alan T Hirsch Journal: Circulation Date: 2017-02-16 Impact factor: 29.690
Authors: Anush V Karapetyan; Yuri M Klyachkin; Samy Selim; Manjula Sunkara; Khaled M Ziada; Donald A Cohen; Ewa K Zuba-Surma; Janina Ratajczak; Susan S Smyth; Mariusz Z Ratajczak; Andrew J Morris; Ahmed Abdel-Latif Journal: Stem Cells Dev Date: 2013-02-19 Impact factor: 3.272
Authors: Xiuchun Li; Pan He; Xiao-Liang Wang; Shuning Zhang; Neil Devejian; Edward Bennett; Chuanxi Cai Journal: Free Radic Biol Med Date: 2018-05-14 Impact factor: 7.376